Categories AlphaGraphs, Finance

Infographic: Highlights of Morgan Stanley (MS) Q2 2022 earnings report

Banking giant Morgan Stanley (NYSE: MS) on Thursday reported lower earnings and revenues for the second quarter of 2022. The company’s stock dropped soon after the announcement.

Morgan Stanley Q2 2022 earnings infographic

Net income applicable to shareholders was $2.39 billion or $1.39 per share in the second quarter of 2022, compared to $3.41 billion or $1.85 per share in the same period a year ago.  Adjusted earnings dropped to $1.44 per share from $1.89 per share last year.

The bottom line was hurt by an11% decrease in revenues to $13.13 billion. The company delivered ROTCE of 13.8%, or 14.3% excluding the impact of integration-related expenses.

Check this space to read management/analysts’ comments on Morgan Stanley’s Q2 2022 earnings

Shares of Morgan Stanley declined early Thursday following the earnings announcement, after closing the last session lower.

Prior Performance

  • Morgan Stanley Q1 2022 earnings infographic
  • Morgan Stanley Q4 2021 earnings infographic
  • Morgan Stanley Q3 2021 earnings infographic


Stocks you may like:

Bank of America (BAC) Stock

Wells Fargo (WFC) Stock

JPMorgan Chase (JPM) Stock

Citigroup (C) Stock

Goldman Sachs (GS) Stock

Morgan Stanley (MS) Stock


Most Popular

WMT Earnings: All you need to know about Walmart’s Q2 2023 earnings results

Walmart Inc. (NYSE: WMT) reported second quarter 2023 earnings results today. Total revenue increased 8.4% year-over-year to $152.9 billion. Revenues grew 9.1% in constant currency. Consolidated net income attributable to

Rivian (RIVN) reaffirms production goals. Will it be a smooth ride?

The evolution of the electric vehicle industry accelerated in recent years even as innovations in battery technology and affordability brought EVs into the mainstream. Encouraged by the success of market

Pfizer (PFE): A look at the headwinds and tailwinds this pharma giant faces in the near term

Shares of Pfizer Inc. (NYSE: PFE) were down on Monday. The stock has dropped 15% year-to-date and there is a mixed sentiment surrounding the company’s growth prospects. Pfizer has benefited

Add Comment
Viewing Highlight